NewsBenzinga바클레이즈, 사브라 헬스케어 리츠 투자의견 ‘중립’ 유지, 목표주가 21달러로 하향 바클레이즈, 사브라 헬스케어 리츠 투자의견 ‘중립’ 유지, 목표주가 21달러로 하향 Benzinga 2026.10.13 16:32 (GMT+0) Open on Benzinga Other news PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17 What to Expect From Advanced Micro Devices’ Q3 2026 Earnings Report Here's What to Expect From Uber’s Next Earnings Report Aflac’s Q3 2026 Earnings: What to Expect Marathon Petroleum Earnings Preview: What to Expect American International Group’s Quarterly Earnings Preview: What You Need to Know
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17
